Skip to main content
Premium Trial:

Request an Annual Quote

World Fusion, Lumenogix to Integrate Technologies to Enable NGS-based Drug Discovery

NEW YORK (GenomeWeb) – World Fusion and Lumenogix today announced a strategic partnership to integrate their technologies.

World Fusion will integrate its Life Sciences Knowledge Bank for accelerating drug discovery with Lumenogix's Bioinformatics-in-a-Box for next-generation sequencing data analysis. The new system will link NGS-processed results managed by Lumenogix's technology with small molecule and protein data managed by LSKB, enabling pharma to take advantage of the opportunities offered by NGS technology, the partners said.

Financial and other terms of the deal were not disclosed.

"World Fusion offers us an opportunity to deliver chemical, gene, protein, and disease information to our clients," Lumenogix CEO Boris Umylny said in a statement. "Together with World Fusion we will deliver a complete solution to the pharmaceutical industry and help them solve the data mining challenges inherent in high-throughput sequencing data."

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.